| アブストラクト | Glucagon-like peptide-1 receptor agonists are increasingly prescribed to reproductive-aged patients, yet pharmacovigilance data on menstrual outcomes remain sparse. Using the FDA Adverse Event Reporting System data through March 2026, we performed disproportionality and Bayesian analyses restricted to female patients aged 12-55 years in a retrospective cohort study. Semaglutide demonstrated the broadest signal profile, with disproportionate reporting of heavy menstrual bleeding, intermenstrual bleeding, menstrual clots, oligomenorrhea, and anovulatory cycles. Tirzepatide generated signals for intermenstrual bleeding and menstrual clots. Liraglutide produced no significant signals. These findings suggest pleiotropic effects on menstrual physiology and may support inclusion of menstrual health in counseling for reproductive-aged patients. |
|---|
| ジャーナル名 | Obstetrics and gynecology |
|---|
| Pubmed追加日 | 2026/7/9 |
|---|
| 投稿者 | Frey, Connor; Etminan, Mahyar |
|---|
| 組織名 | Department of Medicine, University of British Columbia, and Epilytics, Vancouver,;British Columbia, Canada. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42424619/ |
|---|
